Literature DB >> 24722152

Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma.

Tatsuji Mizukami1, Kouya Shiraishi, Yoko Shimada, Hideaki Ogiwara, Koji Tsuta, Hitoshi Ichikawa, Hiromi Sakamoto, Mamoru Kato, Tatsuhiro Shibata, Takashi Nakano, Takashi Kohno.   

Abstract

BACKGROUND: Oncogenic RET fusion, caused by an inversion in chromosome 10, was recently identified as a driver mutation for the development of lung adenocarcinoma (LADC). Nevertheless, the molecular mechanism(s) underlying the rearrangement of the RET locus during lung carcinogenesis are unknown.
METHODS: Genomic segments containing breakpoint junctions for RET fusions were cloned and analyzed by genomic polymerase chain reaction and genome capture sequencing using a next-generation sequencer to identify the mechanisms involved in DNA strand breaks and illegitimate joining of DNA ends. Of the 18 cases studied, 16 were identified by screening 671 LADC cases and two were previously published.
RESULTS: Almost all (17 of 18, 94%) of the breakpoints in RET were located within a 2.0-kb region spanning exon 11 to intron 11 and no breakpoint occurred within 4 bp of any other. This suggested that as in papillary thyroid carcinoma, DNA strand breaks formed at nonspecific sites within this region trigger RET fusion. Just over half of the RET fusions in LADC (10 of 18, 56%) were caused by simple reciprocal inversion, and two DNA-repair mechanisms, namely nonhomologous end joining and break-induced replication, were deduced to have contributed to the illegitimate joining of the DNA ends.
CONCLUSIONS: Oncogenic RET fusion in LADC occurs through multiple pathways and involves the illegitimate repair of DNA strand breaks through mechanisms different from those identified in papillary thyroid carcinoma, where RET fusion also functions as a driver mutation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24722152     DOI: 10.1097/JTO.0000000000000135

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  20 in total

Review 1.  Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.

Authors:  Takashi Kohno; Takashi Nakaoku; Koji Tsuta; Katsuya Tsuchihara; Shingo Matsumoto; Kiyotaka Yoh; Koichi Goto
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 2.  Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.

Authors:  Alexander Drilon; Zishuo I Hu; Gillianne G Y Lai; Daniel S W Tan
Journal:  Nat Rev Clin Oncol       Date:  2017-11-14       Impact factor: 66.675

3.  Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.

Authors:  Thereasa A Rich; Karen L Reckamp; Young Kwang Chae; Robert C Doebele; Wade T Iams; Michael Oh; Victoria M Raymond; Richard B Lanman; Jonathan W Riess; Thomas E Stinchcombe; Vivek Subbiah; David R Trevarthen; Stephen Fairclough; Jennifer Yen; Oliver Gautschi
Journal:  Clin Cancer Res       Date:  2019-07-12       Impact factor: 12.531

Review 4.  State-of-the-Art Strategies for Targeting RET-Dependent Cancers.

Authors:  Vivek Subbiah; Dong Yang; Vamsidhar Velcheti; Alexander Drilon; Funda Meric-Bernstam
Journal:  J Clin Oncol       Date:  2020-02-21       Impact factor: 44.544

Review 5.  The importance of the RET gene in thyroid cancer and therapeutic implications.

Authors:  Domenico Salvatore; Massimo Santoro; Martin Schlumberger
Journal:  Nat Rev Endocrinol       Date:  2021-02-18       Impact factor: 43.330

6.  Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients.

Authors:  Junnan Feng; Yan Li; Bing Wei; Lei Guo; Weihua Li; Qingxin Xia; Chengzhi Zhao; Jiawen Zheng; Jiuzhou Zhao; Rui Sun; Yongjun Guo; Luka Brcic; Taiki Hakozaki; Jianming Ying; Jie Ma
Journal:  Transl Lung Cancer Res       Date:  2022-04

Review 7.  Molecular Process Producing Oncogene Fusion in Lung Cancer Cells by Illegitimate Repair of DNA Double-Strand Breaks.

Authors:  Yoshitaka Seki; Tatsuji Mizukami; Takashi Kohno
Journal:  Biomolecules       Date:  2015-09-30

8.  A secondary RET mutation in the activation loop conferring resistance to vandetanib.

Authors:  Takashi Nakaoku; Takashi Kohno; Mitsugu Araki; Seiji Niho; Rakhee Chauhan; Phillip P Knowles; Katsuya Tsuchihara; Shingo Matsumoto; Yoko Shimada; Sachiyo Mimaki; Genichiro Ishii; Hitoshi Ichikawa; Satoru Nagatoishi; Kouhei Tsumoto; Yasushi Okuno; Kiyotaka Yoh; Neil Q McDonald; Koichi Goto
Journal:  Nat Commun       Date:  2018-02-12       Impact factor: 14.919

Review 9.  Gene aberrations for precision medicine against lung adenocarcinoma.

Authors:  Motonobu Saito; Kouya Shiraishi; Hideo Kunitoh; Seiichi Takenoshita; Jun Yokota; Takashi Kohno
Journal:  Cancer Sci       Date:  2016-05-25       Impact factor: 6.716

10.  Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations.

Authors:  Frédéric Dugay; Francisco Llamas-Gutierrez; Marjory Gournay; Sarah Medane; François Mazet; Dan Christian Chiforeanu; Emmanuelle Becker; Régine Lamy; Hervé Léna; Nathalie Rioux-Leclercq; Marc-Antoine Belaud-Rotureau; Florian Cabillic
Journal:  Oncotarget       Date:  2017-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.